Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.800
-0.130 (-4.44%)
At close: Aug 28, 2026, 4:00 PM EDT
2.810
+0.010 (0.36%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $733.00K in the quarter ending June 30, 2026, a decrease of -88.31%. This brings the company's revenue in the last twelve months to $1.58M, down -76.20% year-over-year. In the year 2025, Ovid Therapeutics had annual revenue of $7.25M with 1,181.27% growth.
Revenue (ttm)
$1.58M
Revenue Growth
-76.20%
P/S Ratio
345.44
Revenue / Employee
$68,826
Employees
23
Market Cap
546.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.25M | 6.69M | 1,181.27% |
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 116.93M |
| Editas Medicine | 47.01M |
| Scribe Therapeutics | 36.28M |
| Prelude Therapeutics | 22.42M |
| Capricor Therapeutics | 11.13M |
| ProKidney | 818.00K |
| Artiva Biotherapeutics | 251.00K |
| Entera Bio | 42.00K |
OVID News
- 13 days ago - Ovid Therapeutics reports Q2 EPS (8c), consensus (10c) - TheFly
- 16 days ago - Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - GlobeNewsWire
- 16 days ago - Ovid Therapeutics Slides: Corporate presentation - Filings
- 16 days ago - Ovid Therapeutics Quarterly report: Q2 2026 - Filings
- 16 days ago - Ovid Therapeutics Earnings release: Q2 2026 - Filings
- 26 days ago - Ovid Therapeutics price target raised to $9 from $7 at Oppenheimer - TheFly
- 7 weeks ago - Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed - TheFly
- 7 weeks ago - Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development - GlobeNewsWire